A: Baseline A1C/fasting glucose , lipids , CMP , and other markers as indicated
To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
Here are the three most researched peptides and what sets each apart
It readily passes through the gut mucosal barrier and provides localized anti-inflammatory benefits to intestinal tissue
Compliance requirements and availability may vary by jurisdiction.